187 related articles for article (PubMed ID: 26460952)
21. Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis.
Young A; Ngiow SF; Madore J; Reinhardt J; Landsberg J; Chitsazan A; Rautela J; Bald T; Barkauskas DS; Ahern E; Huntington ND; Schadendorf D; Long GV; Boyle GM; Hölzel M; Scolyer RA; Smyth MJ
Cancer Res; 2017 Sep; 77(17):4684-4696. PubMed ID: 28652244
[TBL] [Abstract][Full Text] [Related]
22. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.
Yang H; Higgins B; Kolinsky K; Packman K; Go Z; Iyer R; Kolis S; Zhao S; Lee R; Grippo JF; Schostack K; Simcox ME; Heimbrook D; Bollag G; Su F
Cancer Res; 2010 Jul; 70(13):5518-27. PubMed ID: 20551065
[TBL] [Abstract][Full Text] [Related]
23. Gossypin as a novel selective dual inhibitor of V-RAF murine sarcoma viral oncogene homolog B1 and cyclin-dependent kinase 4 for melanoma.
Bhaskaran S; Dileep KV; Deepa SS; Sadasivan C; Klausner M; Krishnegowda NK; Tekmal RR; VandeBerg JL; Nair HB
Mol Cancer Ther; 2013 Apr; 12(4):361-72. PubMed ID: 23543365
[TBL] [Abstract][Full Text] [Related]
24. Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/β-catenin activation.
Conrad WH; Swift RD; Biechele TL; Kulikauskas RM; Moon RT; Chien AJ
Cell Cycle; 2012 Oct; 11(20):3724-30. PubMed ID: 22895053
[TBL] [Abstract][Full Text] [Related]
25. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
26. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor.
Caporali S; Alvino E; Lacal PM; Levati L; Giurato G; Memoli D; Caprini E; Antonini Cappellini GC; D'Atri S
Int J Oncol; 2016 Sep; 49(3):1164-74. PubMed ID: 27572607
[TBL] [Abstract][Full Text] [Related]
27. Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib.
Blachly JS; Lozanski G; Lucas DM; Grever MR; Kendra K; Andritsos LA
J Natl Compr Canc Netw; 2015 Jan; 13(1):9-13; quiz 13. PubMed ID: 25583765
[TBL] [Abstract][Full Text] [Related]
28. Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition.
Phadke M; Remsing Rix LL; Smalley I; Bryant AT; Luo Y; Lawrence HR; Schaible BJ; Chen YA; Rix U; Smalley KSM
Mol Oncol; 2018 Jan; 12(1):74-88. PubMed ID: 29112787
[TBL] [Abstract][Full Text] [Related]
29. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
[TBL] [Abstract][Full Text] [Related]
30. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
Shi H; Kong X; Ribas A; Lo RS
Cancer Res; 2011 Aug; 71(15):5067-74. PubMed ID: 21803746
[TBL] [Abstract][Full Text] [Related]
31. Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma.
Sharma A; Madhunapantula SV; Gowda R; Berg A; Neves RI; Robertson GP
Am J Pathol; 2013 Apr; 182(4):1151-62. PubMed ID: 23416158
[TBL] [Abstract][Full Text] [Related]
32. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
[TBL] [Abstract][Full Text] [Related]
33. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
[TBL] [Abstract][Full Text] [Related]
34. NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo.
Jalili A; Mertz KD; Romanov J; Wagner C; Kalthoff F; Stuetz A; Pathria G; Gschaider M; Stingl G; Wagner SN
PLoS One; 2013; 8(7):e69064. PubMed ID: 23935925
[TBL] [Abstract][Full Text] [Related]
35. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM
Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471
[TBL] [Abstract][Full Text] [Related]
36. Dabrafenib in the treatment of advanced melanoma.
Medina T; Amaria MN; Jimeno A
Drugs Today (Barc); 2013 Jun; 49(6):377-85. PubMed ID: 23807941
[TBL] [Abstract][Full Text] [Related]
37. Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma.
Nassar KW; Hintzsche JD; Bagby SM; Espinoza V; Langouët-Astrié C; Amato CM; Chimed TS; Fujita M; Robinson W; Tan AC; Schweppe RE
Mol Cancer Ther; 2021 Oct; 20(10):2049-2060. PubMed ID: 34376578
[TBL] [Abstract][Full Text] [Related]
38. Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.
Lassen A; Atefi M; Robert L; Wong DJ; Cerniglia M; Comin-Anduix B; Ribas A
Mol Cancer; 2014 Apr; 13():83. PubMed ID: 24735930
[TBL] [Abstract][Full Text] [Related]
39. Potent Imidazothiazole-based Inhibitor of BRAF V600E Overcomes Acquired Resistance
Poudel M; Kim G; Bhattarai PY; Shin S; Zaraei SO; Oh CH; Choi HS
Anticancer Res; 2022 Jun; 42(6):2911-2921. PubMed ID: 35641256
[TBL] [Abstract][Full Text] [Related]
40. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor.
Curry JL; Falchook GS; Hwu WJ; Torres-Cabala CA; Duvic M; Tetzlaff MT; Prieto VG
Am J Dermatopathol; 2013 Feb; 35(1):125-8. PubMed ID: 22878367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
